肺部耐碳青霉烯类肺炎克雷伯菌感染/定植患者死亡的相关危险因素分析
田丽丽1 王珊珊2 赵建平3 张叶毛4▲
1.内蒙古自治区人民医院保健所,内蒙古呼和浩特 010010;
2.内蒙古医科大学内蒙古临床医学院,内蒙古呼和浩特 010010;
3.内蒙古自治区人民医院检验科,内蒙古呼和浩特 010010;
4.内蒙古医科大学附属医院感染科,内蒙古呼和浩特 010050
Analysis on risk factors associated with death in patients with pulmonary carbapenem-resistant Klebsiella pneumoniae infection / colonization
TIAN Lili1 WANG Shanshan2 ZHAO Jianping3 ZHANG Yemao4▲
1.Department of Care, Inner Mongolia People’s Hospital, Inner Mongolia Autonomous Region, Hohhot 010010, China;
2.Inner Mongolia Clinical Medical College, Inner Mongolia Medical University, Inner Mongolia Autonomous Region, Hohhot 010010, China;
3.Department of Clinical Laboratory, Inner Mongolia People’s Hospital, Inner Mongolia Autonomous Region, Hohhot 010010, China;
4.Department of Infection, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region, Hohhot 010050, China
摘要 目的 分析肺部感染/定植耐碳青霉烯类肺炎克雷伯菌(CRKP)患者死亡的相关危险因素。 方法 收集2017年1月—2019年6月内蒙古自治区人民医院呼吸道标本培养出CRKP的住院患者190例,进行一般资料分析和死亡相关的单(多)因素logistic回归分析。 结果 单因素logistic回归分析结果显示,除合并高血压病、入院时脏器损伤≥3个部位和使用氨基糖苷类抗生素因素外,其他15个因素与肺部CRKP感染/定植患者死亡均相关,差异均有统计学意义(均P < 0.05)。多因素logistic回归分析显示,年龄≥65岁[OR = 3.578,95%CI(1.028~12.451),P = 0.034]、男性[OR = 7.030,95%CI(1.164~42.463),P = 0.045]、合并糖尿病[OR = 12.888,95%CI(1.967~84.421),P = 0.008]、使用机械通气[OR = 14.967,95%CI(2.708~82.724),P = 0.002]、有手术史[OR = 28.026,95%CI(4.964~158.237),P < 0.001]和使用青霉素类[OR = 80.626,95%CI(8.263~786.737),P < 0.001]、头孢菌素类[OR = 25.757, 95%CI(1.149~577.407),P = 0.041]药物是肺部CRKP感染/定植患者死亡的独立危险因素。结论 根据肺部感染/定植CRKP患者死亡的相关危险因素分析,临床上应尽量避免一些侵袭性操作,合理应用抗菌药物,加强高危人群的管理,减少和预防CRKP感染的发生。
关键词 :
感染 ,
碳青霉烯类 ,
肺炎克雷伯菌 ,
耐碳青霉烯类肺炎克雷伯菌 ,
危险因素
Abstract :Objective To analyze the risk factors associated with death in patients with pulmonary infection / colonization of carbapenem-resistant Klebsiella pneumoniae (CRKP). Methods A total of 190 inpatients with CRKP cultured from respiratory tract specimens in Inner Mongolia People’s Hospital from January 2017 to June 2019 were collected for general data analysis and single (multiple) logistic regression analysis of mortality. Results The results of single logistic regression analysis showed that 15 other factors were correlated with death of patients with pulmonary CRKP infection /colonization, except for complications of hypertension, organ injury ≥ 3 sites on admission and the use of aminoglycoside antibiotics, with statistical significance (all P < 0.05). Multivariate logistic regression analysis showed that age ≥65 years (OR = 3.578, 95%CI [1.028-12.451], P = 0.034), male (OR = 7.030, 95%CI [1.164-42.463], P = 0.045), with diabetes (OR = 12.888, 95%CI [1.967-84.421], P = 0.008), use of mechanical ventilation (OR = 14.967, 95%CI [2.708-82.724], P = 0.002), history of surgical (OR = 28.026, 95%CI[4.964-158.237], P < 0.001) and use of penicillin (OR = 80.626, 95%CI [8.263-786.737], P < 0.001), cephalosporins (OR = 25.757, 95%CI [1.149-577.407], P = 0.041) were independent risk factors for death in patients with pulmonary infection/colonization of CRKP. Conclusion According to the independent risk factor analysis of CRKP infection, some invasive procedures should be avoided as far as possible in clinical practice, antimicrobial agents should be used rationally, management of high-risk population should be strengthened, and the occurrence of CRKP infection should be reduced and prevented.
Key words :
Infection
Penicillium carbon alkene
Klebsiella pneumoniae
Carbapenem-resistant Klebsiella pneumoniae
Risk factors
基金资助: 内蒙古自治区自然科学基金项目(2017MS08144);
内蒙古自治区科技计划项目(201702113)。
通讯作者:
▲通讯作者
引用本文:
田丽丽1 王珊珊2 赵建平3 张叶毛4▲. 肺部耐碳青霉烯类肺炎克雷伯菌感染/定植患者死亡的相关危险因素分析[J]. 中国医药导报, 2021, 18(8): 118-121,136.
TIAN Lili1 WANG Shanshan2 ZHAO Jianping3 ZHANG Yemao4▲. Analysis on risk factors associated with death in patients with pulmonary carbapenem-resistant Klebsiella pneumoniae infection / colonization. 中国医药导报, 2021, 18(8): 118-121,136.
链接本文:
http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2021/V18/I8/118
[1] 罗燕萍,张秀菊,徐雅萍,等.产超广谱β-内酰胺酶肺炎克雷伯菌和大肠埃希菌的分布及其耐药性研究[J].中华医院感染学杂志,2006,16(1):101-104.
[2] 文细毛,任南,吴安华,等.全国医院感染监控网医院感染病原菌分布及变化趋势[J].中华医院感染学杂志,2011, 21(2):350-355.
[3] 尚红,王毓三,申子瑜.全国临床检验操作规程[M].4版.北京:人民卫生出版社,2015:574-773.
[4] Clinical and Laboratory Standards Institute M100S Performance Standards for Antimicrobial Susceptibility Testing:Twenty-Sixth Edition [S]. Wayne,PA:CLSI,2016.
[5] MacKenzie FM,Forbes KJ,Dorai-John T,et al. Emergence of a carbapenem-resistant Klebsiella pneumoniae [J]. Lancet,1997,350:783.
[6] Bratu S,Landman D,Haag R,et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City:a new threat to our antibiotic armamentarium [J]. Arch Intern Med,2005,165(12):1430-1435.
[7] 方金林,黄燕周,叶红芳.ICU成人患者呼吸机相关性肺炎危险因素的meta分析[J].中国医药导报,2020,17(11):102-106,110.
[8] Bogan C,Kaye KS,Chopra T,et al. Outcomes of carbapenem-resistant Enterobacteriaceae isolation:matched analysis [J]. Am J Infect Control,2014,42(6):612-620.
[9] 刘洁,杨晶,高立芳,等.耐碳青霉烯类肺炎克雷伯菌的耐药性及危险因素分析[J].中华医院感染学杂志,2020, 30(8):1223-1227.
[10] 唐洪影,李静,宋缘缘,等.耐碳青霉烯类肺炎克雷伯菌感染及预后相关因素分析[J].天津医科大学学报,2019, 25(3):271-274,284.
[11] 唐丽玲,张培金,钱丽华,等.我国碳青霉烯类耐药肺炎克雷伯菌感染危险因素Meta分析[J].中国消毒学杂志,2019,36(3):199-202,205.
[12] 陈蕾,田俊华,贾磊,等.重症监护室内医院获得性耐碳青霉烯类肺炎克雷伯菌肺炎的危险因素分析[J].国际流行病学传染病学杂志,2020,47(3):231-234.
[13] 江雪艳,杨琦,袁源,等.心胸外科术后继发耐碳青霉烯类肺炎克雷伯菌的临床观察及经验分享[J].中国心血管病研究,2020,18(7):635-638.
[14] 孙雁,郑虹,张坚磊,等.儿童肝移植术后耐碳青霉烯类肠杆菌科感染临床特点分析[J].中华儿科杂志,2020, 58(8):640-645.
[15] 马联胜,赵佳佳,牛小媛.重症脑血管病患者卒中相关性肺炎的危险因素及预后分析[J].中华临床医师杂志:电子版,2017,11(20):2307-2310.
[16] 梁章荣,李旷怡,张英俭,等.缺血性脑卒中患者并发重症肺炎的病原菌与影响因素分析[J].中华医院感染学杂志,2019,29(11):1656-1659.
[17] 李旷怡,冯锦防,吴智鑫,等.急性脑卒中患者并发重症肺炎的危险因素及病原菌分析[J].中国医药导报,2020, 17(19):101-104.
[18] 杨顺权.ICU患者肺部感染危险因素分析及预防研究[J].心血管外科杂志:电子版,2020,9(1):93.
[19] 曹鹏.ICU脑卒中患者并发肺部感染的危险因素调查及护理对策分析[J].实用临床护理学电子杂志,2020,5(23):126,157.
[20] 郝伟利.急诊内科危重症心力衰竭患者合并肺部感染的危险因素分析[J].中国保健营养,2020,30(26):346.
[21] Lewis K. Riddle of Biofilm Resistance [J]. Antimicrob Agents Chemother,2001,45(4):999-1007.
[22] Girmenia C,Rossolini GM,Piciocchi A,et al. Infection by carbapenem-resistant Klebsiella pneumoniae in SCT recipents:a nationwide retrospctive survey from Italy [J]. Bone Marrow Trans Plant,2015,50(2):282-288.
[23] Wunderink RG,Giamarellos-Bourboulis EJ,Rahav G,et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections:The TANGO Ⅱ Randomized Clinical Trial [J]. Infect Dis Ther,2018,7(4):439-455.
[24] Fortini A,Faraone A,Di Pietro M,et al. Antimicrobial stewardship in an internal medicine ward:effects on antibiotic consumption and on the use of carbapenems [J]. Intern Emerg Med,2018,13(8):1219-1226.
[25] 张志军,鹿麟,牛法霞,等.耐碳青霉烯类肺炎克雷伯菌的耐药机制与分子流行病学特征[J].中国感染控制杂志,2018,17(9):759-763.
[26] 杨健.院内获得耐碳青霉烯类抗菌药物肺炎克雷伯菌感染的危险因素分析[J].吉林医学,2021,42(1):59-61.
[27] 唐丽玲,张培金,钱丽华,等.我国碳青霉烯类耐药肺炎克雷伯菌感染危险因素Meta分析[J].中国消毒学杂志,2019,36(3):199-202,205.
[28] 程秦,沈宁,郑佳佳,等.耐碳青霉烯肺炎克雷伯菌肺炎患者死亡相关因素分析[J].中国临床药理学杂志,2018, 34(14):1703-1706.
[1]
任静. 平战结合模式下公立医院纪检监督工作的实践与思考 [J]. 中国医药导报, 2021, 18(9): 193-196.
[2]
赵世娇1 门慧1 王莹1 李施新1 闫羽1 代玲玲1 陈宝鑫2 金香兰2. 轻型急性缺血性卒中患者认知障碍的危险因素研究 [J]. 中国医药导报, 2021, 18(8): 74-77,81.
[3]
蔡明建1 王虎2 尚昆2 庄岩2 田丁2 张堃2. 骨折患者出院后下肢深静脉血栓复发特点及危险因素分析 [J]. 中国医药导报, 2021, 18(8): 122-125.
[4]
吴亚亭 李爱爱▲ 姚辉 许珏. 重型闭合性颅脑损伤开颅术后患者肺部感染因素研究 [J]. 中国医药导报, 2021, 18(8): 130-132,144.
[5]
余建华1 张艳洪1 邹小凤1 朱文婷1 李鑫2 陈美琪3. 中性粒细胞CD64指数和单核细胞HLA-DR在细菌与病毒性感染中的诊断价值 [J]. 中国医药导报, 2021, 18(6): 34-37,53.
[6]
苑宝文1 李筹忠2 陈瑜峰3 魏玲3. 血清UA水平与脑梗死患者颅内外动脉粥样硬化性狭窄的关系 [J]. 中国医药导报, 2021, 18(5): 61-64.
[7]
马珊珊1 王瑞萍1 彭菲1 邢艳晖1 胡晓颖1 王秀芳2. 急性脑梗死患者早期认知功能障碍的相关危险因素 [J]. 中国医药导报, 2021, 18(5): 73-75,79.
[8]
安妍 高建勤 郭彩红 朱巍. 中老年2型糖尿病患者合并DR的危险因素分析 [J]. 中国医药导报, 2021, 18(3): 59-61,66.
[9]
王斌1 张文贤2 廖敏捷2 张堃2 苏奇3 李佳霖3 严其凯3 赵建伟3. 闭合性胫骨骨折内固定术后切口感染相关危险因素分析 [J]. 中国医药导报, 2021, 18(3): 79-83.
[10]
何松蔚1 王俊宏2▲ 赵骞1. 儿童过敏性紫癜复发相关危险因素的meta分析 [J]. 中国医药导报, 2021, 18(3): 105-110.
[11]
伊争伟1 左红1 王彦琛2▲. 左心房容积指数与急性冠脉综合征患者心脏不良事件的关系及其诊断价值 [J]. 中国医药导报, 2021, 18(2): 52-55,60.
[12]
谭小光. 儿童原发性肠套叠220例的临床特点及危险因素分析 [J]. 中国医药导报, 2021, 18(2): 86-89.
[13]
耿蕾1 吴蔚桦1 黄超越1 刘建1,2. 新增老年血液透析患者反复住院和死亡危险因素分析 [J]. 中国医药导报, 2020, 17(8): 134-138.
[14]
任云1 徐建忠1 杨海波2 张晋丹1. 肉芽肿性小叶性乳腺炎短期复发的高危因素研究 [J]. 中国医药导报, 2020, 17(8): 144-147.
[15]
任迪1 李颖1 曾晶晶1 谭婷婷2. 高通量测序在重症肺部感染患者中的应用效果 [J]. 中国医药导报, 2020, 17(7): 94-97.